Nemaura Medical
Nemaura Medical
NMRD
OTC
0.00
USD
0.00%
About
Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The Company is commercializing sugarBEAT and proBEAT. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a continuous glucose monitoring system (CGM), sugarBEAT.
The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and also be used to screen pre-diabetic patients. The sugarBEAT device extracts from analytes, such as glucose, from the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm.
The SugarBEAT works by extracting glucose from the skin into a chamber in the patch that is in direct contact with an electrode-based sensor. The proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 9.6K |
| Three Month Average Volume | 165.3K |
| High Low | |
| Fifty-Two Week High | 0.59 USD |
| Fifty-Two Week Low | 0.0292 USD |
| Fifty-Two Week High Date | 13 Sep 2023 |
| Fifty-Two Week Low Date | 06 May 2024 |
| Price and Volume | |
| Current Price | 0.031 USD |
| Beta | 0 |
| Relative Price Change | |
| Four Week Relative Price Change | -8.30% |
| Thirteen Week Relative Price Change | -40.22% |
| Twenty-Six Week Relative Price Change | -64.76% |
| Fifty-Two Week Relative Price Change | -94.62% |
| Year-to-Date Relative Price Change | -88.05% |
| Price Change | |
| One Day Price Change | 0.00% |
| Thirteen Week Price Change | -36.02% |
| Twenty-Six Week Price Change | -61.25% |
| Five Day Price Change | -3.73% |
| Fifty-Two Week Price Change | -93.26% |
| Year-to-Date Price Change | -85.84% |
| Month-to-Date Price Change | -3.13% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -0.4088 USD |
| Book Value Per Share (Most Recent Quarter) | -0.61685 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -0.42209 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -0.62509 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.25086 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.0031 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.56852 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.37865 USD |
| Normalized (Last Fiscal Year) | -0.46971 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.56852 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.37865 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.56852 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.37865 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.34967 USD |
| Cash Per Share (Most Recent Quarter) | 0.00476 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.55449 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.357 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.34214 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -5,265 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -18,358.96% |
| Pretax Margin (5 Year) | -7,608.67% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 2.22% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -12,454.88% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -5,337.40% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -18,358.96% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -7,384.83% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -100.00% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -100.00% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 64.14% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -5.03% |
| EPS Change (Trailing Twelve Months) | 30.46% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 19.5M |
| Net Debt (Last Fiscal Year) | 9.9M |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 16 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | -100,000 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 1 |
| Quick Ratio (Most Recent Quarter) | 0 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 0 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -8,991,000 |
| Free Cash Flow (Trailing Twelve Months) | -9,742,500 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -1 |
| Net Interest Coverage (Trailing Twelve Months) | -1 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | -100,000 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -77.15% |
| Return on Assets (Trailing Twelve Months) | -117.49% |
| Return on Assets (5 Year) | -58.18% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -99,999.99% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -728.82% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -99,999.99% |
| Return on Investment (Trailing Twelve Months) | -99,999.99% |
| Return on Investment (5 Year) | -131.96% |